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Resumo 
 
O Síndrome Doloroso Vesical/Cistite Intersticial (BPS/IC, do inglês bladder pain 
syndrome/ interstitial cystitis) é um síndrome crónico e doloroso, cuja etiologia 
permanece desconhecida. Doentes com esta patologia apresentam uma 
hiperatividade do sistema nervoso simpático, caracterizada pelo aumento da 
expressão de tirosina hidroxilase na bexiga, pelo aumento dos níveis de noradrenalina 
na urina e pelo aumento da pressão sanguínea e ritmo cardíaco durante a distensão 
da bexiga. Estes doentes também apresentam um aumento da expressão do TRPV1 
na bexiga. A hiperatividade simpática pode também ser observada em várias 
patologias dolorosas em humanos e em modelos animals de dor. 
Estudos anteriores demonstraram que a estimulação crónica adrenérgica com 
fenilefrina em ratos induz um comportamento de dor, aumenta a frequência urinária e 
disfunção do urotélio, o que simula o BPS/IC. A dor e o aumento da frequência urinária 
são dependentes dos aferentes primários sensíveis à capsaicina, um agonista do 
TRPV1. A desensibilização destes aferentes primários por doses elevadas de 
capsaicina reverte os efeitos induzidos pela fenilefrina, sugerindo uma possível relação 
entre a atividade adrenérgica e a atividade nociceptiva (como o próprio TRPV1 ou com 
outros recetores como os recetores canabinóides, por exemplo). 
Este trabalho teve três objetivos principais. O primeiro objetivo foi demonstrar o 
envolvimento dos adrenocetores no aparecimento dos sintomas de BPS/IC, 
caracterizando qual o subtipo de adrenorecetor que está envolvido no aparecimento 
da dor e nas alterações histológicas observadas em animais submetidos a estimulação 
crónica adrenérgica com fenilefrina. O segundo objetivo foi avaliar a relação entre os 
adrenocetores e o TRPV1 durante a estimulação crónica adrenérgica com fenilefrina. 
O terceiro objetivo foi verificar como é que os endocanabinóides modulam a dor 
vesical e a hiperatividade durante a cistite. 
Para avaliar qual o subtipo de adrenocetor que está envolvido no aparecimento 
da dor, aos ratos Wistar fêmeas injetados diariamente com 2.5 mg/Kg de fenilefrina 
(subcutânea durante 14 dias) foi-lhes administrado oralmente os seguintes 
antagonistas dos α1 – adrenocetores: Silodosina, Naftopidil ou Prazosina. Ao dia 15, 
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os animais foram anestesiados com uretano (1.2 g/Kg) e as cistometrias foram 
realizadas durante 2h. Depois deste período, os animais foram perfundidos com 
paraformaldeído e a bexiga e o segmento L6 da medula espinhal foram colhidos. A 
bexiga dos animais foi cortada e corada com Hematoxilina-Eosina para analisar a 
morfologia do urotélio e com Azul de Toluidina para estudar os mastócitos. Os cortes 
de bexigas foram também sujeitos a uma reação de imunofluorescência contra a 
caspase 3, para analisar a apoptose do urotélio. Os segmentos da região L6 da 
medula espinal foram sujeitos a reação de imunohistoquímica contra a proteína Fos. 
 Para estudar a relação entre os adrenocetores e as vias nociceptivas, um 
grupo de ratinhos mutantes para o TRPV1 foram injetados diariamente com fenilefrina, 
durante 14 dias. O comportamento doloroso foi avaliado nestes animais. Mais ainda, 
um grupo de ratos Wistar fêmeas e respetivos controlos foram injetados diariamente 
com fenilefrina durante 14 dias. No fim do tratamento os animais foram submetidos a 
cistometria com capsaicina. 
Para avaliar se os endocanabinóides modulam a dor vesical e a hiperatividade 
durante a cistite, um grupo de ratos Wistar fêmeas foram instilados com 
lipopolisacarídeo (LPS) e com URB (inibidor da FAAH, do inglês fatty acid amide 
hydrolase), e foi avaliado o comportamento doloroso, bem como o funcionamento da 
bexiga através da cistometria. Estas experiências foram repetidas em animais tratados 
com LPS, URB e antagonistas do recetor canabinóide 1 (CB1), recetor canabinóide 2 
(CB2) e TRPV1 (MJ15, SR144528 e SB366791, respetivamente). Os segmentos L6 da 
medula espinal foram sujeitos a uma reação de imunohistoquímica contra a proteína 
Fos. 
Este trabalho confirmou que a estimulação crónica adrenérgica com fenilefrina 
induz um comportamento de dor, infiltração de mastócitos, apoptose de células 
uroteliais e ativação das vias nociceptivas. A Silodosina (antagonista dos α1A-
adrenorecetores) reduz os efeitos induzidos pela fenilefrina. Para além disso, o TRPV1 
e o CB1 parecem estar envolvidos na hiperatividade da bexiga. 
Assim sendo, podemos afirmar que BPS/IC resulta da interação entre várias 
vias, nomeadamente dos α1A-adrenoreceptores, do TRPV1 e do CB1.  
  
Palavras-chave: Síndrome doloroso vesical/ cistite intersticial; alfa-adrenorecetores; 
TRPV1; CB1; vias nociceptivas 
 
FCUP 
Characterization of an animal model of Bladder painful syndrome/ Interstitial cystitis 
11 
 
 
Abstract 
 
 Bladder painful syndrome/ interstitial cystitis (BPS/IC) is a chronic debilitating 
condition with unknown etiology. Patients with BPS/IC present an increased 
sympathetic activity, characterized by an increase in tyrosine hydroxylase expression in 
the bladder, increased noradrenaline levels in urine and elevated mean blood pressure 
and heart rate during bladder hydrodistention. These patients also present an increase 
in expression of TRPV1 in the bladder. Sympathetic overactivity also can be observed 
in several human painful diseases and in rat pain models.  
 Previous studies showed that chronic adrenergic stimulation with phenylephrine 
(PHE) in rats induced pain behavior, increased voiding frequency and urothelial 
dysfunction, which mimic BPS/IC. Pain and increased frequency where dependent of 
capsaicin sensitive primary afferents activation since desensitization of these fibers 
with high levels of capsaicin reverse the phenylephrine mediated effect, demonstrating 
a possible relation between adrenergic activity and nociceptive activity (like TRPV1 or 
other receptors like cannabinoid receptors, for example).  
Hence, this work had three main goals. The first goal was to demonstrate the 
involvement of adrenoceptors in the appearance of BPS/IC symptoms, characterizing 
which subtypes are involved in the appearance of pain and histological changes 
observed in animals submitted to chronic adrenergic stimulation with phenylephrine. 
The second aim was to evaluate the cross-talk between adrenoceptors and TRPV1 
during chronic adrenergic stimulation with phenylephrine. The third aim was to verify 
how endocannabinoids modulate the bladder pain and hyperactivity during cystitis. 
 To assess which adrenoceptor subtypes are involved in the appearance of pain, 
to female Wistar rats injected with 2.5 mg/Kg/day of phenylephrine (PHE; 
subcutaneously for 14 days) was administrated orally the follow antagonists of 
adrenoceptors: Silodosin, Naftopidil or Prazosin. The visceral pain behavior and 
voiding pattern were analyzed before and 14 days after PHE treatment. At day 15, 
animals were anaesthetized with urethane (1.2 g/Kg) and cystometries were performed 
for 2h. Animals were then perfused with paraformaldehyde and the bladder and L6 
spinal cord segments were harvested. Bladder sections from these animals were 
stained with Hematoxylin-eosin to analyze urothelium morphology, with Toluidine Blue 
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to study mast cells, and immunoreacted (IR) against caspase 3, to investigate 
urothelial apoptosis. L6 spinal cord segments were IR against Fos. 
 Furthermore, to study the cross-talk between adrenoceptors and nociceptive 
pathways, a group of TRPV1 knockout mice were injected with PHE daily for 14 days. 
Visceral pain behavior and cystometry were performed in these animals. Further, a 
group of female Wistar rats was daily injected with phenylephrine for 14 days. At the 
end of treatment, animals were submitted to cystometry with capsaicin. 
To assess if endocannabinoids modulate bladder pain and hyperactivity during 
cystitis, a group of female Wistar rats were instilled with lipopolysaccharide (LPS) and 
URB (inhibitor of FAAH, fatty acid amide hydrolase). Visceral pain behavior and 
cystometry were performed. These experiments were repeated in rats co-treated with 
LPS, URB and antagonists of CB1, CB2 and TRPV1 (MJ15, SR144528 and 
SB366791, respectively). L6 spinal cord segments were IR against Fos. 
 The results confirm that chronic adrenergic stimulation with PHE induce visceral 
pain, mast cells infiltration, apoptosis of urothelial cells and activation of nociceptive 
pathways. Silodosin (antagonist of α1A-adrenoceptor subtype) seem to be more 
effective than naftopidil or prazosin (α1D and α1-adrenoceptor antagonists, respectively) 
to reduce the effects induced by PHE. This work also shows that TRPV1 and CB1 are 
involved in bladder hyperactivity.  
 Thus, it can be affirmed that BPS/IC result the interaction between several 
pathways, namely those involving α1A-adrenoceptors, TRPV1 and CB1. 
 
 
 
 
Keywords: Bladder painful syndrome/ interstitial cystitis; alpha-adrenoceptors; TRPV1; 
CB1; nociceptive pathways 
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I. Introduction 
 
1. Bladder painful syndrome/ Interstitial cystitis (BPS/IC) 
 
1.1 Definition of BPS/IC 
 Bladder Painful Syndrome/Interstitial cystitis (BPS/IC) is a chronic pathology 
characterized by supra-pubic pain  related to bladder filling, frequently accompanied by 
other lower urinary tract symptoms such as increased daytime and night-time 
frequency, in the absence of proven urinary infection or other obvious pathology [1]. It 
is a chronic debilitating and multifactorial syndrome with no long-term effective therapy 
[1, 2]. The principal symptom of this syndrome is suprapubic pain [3], which might be 
felt in other regions rather than the bladder [1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]. 
BPS/IC is more predominant in women [1]. BPS/IC has a great impact in the 
psychological, social, economic, professional and personal life of patients with this 
disease, so much that sometimes small and easy actions like travelling, recreation 
activities with family and sleeping become very hard [1, 2].  
 This syndrome can be divided into two different subtypes: the classic subtype 
and the nonclassic/ nonulcerative subtype [7, 11, 12, 16]. They differ in various 
aspects, like histopathological characteristics, age distribution (patients with non-
ulcerative form being younger than patients with classic form), complications pattern 
and response to treatment [12, 13]. Patients with classic BPS/IC exhibit pelvic pain, an 
increase in urinary frequency and urgency and blood in urine [14]. Five to fifty patients 
develop Hunner´s lesion (figure 1), which is a “circumscript, reddened mucosal area 
with small vessels radiating towards a central scar, with a fibrin deposit or coagulum 
attached to this area. With an increase in bladder distension this site can rupture and 
lead to an edema” [14, 17]. These lesions can be confirmed by cystoscopy with 
hydrodistension under general, epidural or local anesthesia by experienced urologists 
and in some cases it may be necessary to make a biopsy to confirm Hunner´s lesion 
and exclude a carcinoma [14]. Hunner’s lesion may also be confoundable with 
glomerulations. However, the latter are areas of bleeding in the bladder wall and do not 
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lead automatically to a diagnosis of BPS/IC [14]. Presently it is still unclear if the non-
ulcer and classic subtypes represent different stages of a single disease or if they are 
different diseases entities [14]. 
 
 
Figure 1. Hunner´s lesion in bladder from patients with BPS/IC, adapted from ESSIC (European Society for the study of BPS/IC) in 
http://www.essic.eu/video_028images.html. 
 
The designation of this syndrome has changed over the years. Initially, the 
syndrome was called Interstitial Cystitis (IC) due to the presence of “typical cystoscopic 
and histological features” on the bladder wall, which include inflammation in the deeper 
layers of the bladder wall [1, 14, 18]. However, not all patients presented bladder 
inflammation signs. Hence, the term IC was progressively changed to Painful Bladder 
Syndrome (PBS) evidencing bladder pain instead of inflammation. The International 
Continence Society (ICS) define PBS as “the complaint of suprapubic pain related to 
bladder filling, accompanied by other symptoms such as increased daytime and night-
time frequency, in the absence of proven urinary infection or other obvious pathology” 
[19]. However, this definition excluded 34% of the patients having bladder pain and 
being classified by experts to have IC. So, the ESSIC group propose to give it the 
name of bladder painful syndrome (BPS). ESSIC defines that “Bladder painful 
syndrome would be diagnosed on the basis of chronic pelvic pain, pressure or 
discomfort perceived to be related to the urinary bladder accompanied by at least one 
other urinary symptom like persistent urge to void or urinary frequency, of more than 
six weeks duration, in the absence of infection or other identifiable causes. Confusable 
diseases as the cause of symptoms must be excluded. Further documentation and 
classification of BPS might be performed according to findings at cystoscopy with 
hydrosdistention and morphological findings in bladder biopsies” [14, 20]. However, 
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omitting the name “Interstitial cystitis” might cause serious problems in different health 
systems, so it was decided that the name of Bladder Painful Syndrome/Interstitial 
Cystitis could be used during the transition time [14]. 
Therefore, in this thesis, the term BPS/IC will be used now on, even when 
referring to research where the anterior nomenclature was used. 
 
1.2 Etiology of BPS/IC 
The etiology of BPS/IC remains unknown, although several hypotheses have 
been proposed, mostly linked to a dysfunction in the urothelium: Infection [1, 10, 11, 
21, 22], Inflammation [1, 10, 13, 21, 22], Mast cell activation  [1, 2, 11, 12, 21, 22, 23, 
24],  Urothelial dysfunction/ glycosaminoglycan (GAG)-layer defect [1, 2, 10], 
Autoimmune mechanisms [1, 10, 13, 21, 22], Toxic agents [1, 22], among others.  
 
1.3 Diagnosis of BPS/IC 
The absence of a consensus definition for BPS/IC and the fact that the 
symptoms are not specific (symptoms are very similar to other conditions, called 
confoundable diseases) difficult the diagnosis of these patients. So, the diagnosis of 
BPS/IC is a diagnosis of exclusion and the patients can remain undiagnosed for years 
[24]. The diagnosis of BPS/IC, due to the lack of specific markers, is based on 
symptoms described by the patients, such as pain, discomfort or pressure, and 
exclusion of any identifiable infection [2, 7, 10, 22]. BPS/IC diagnosis also includes 
cystoscopy with or without hydrodistention and may include biopsy to analyze mast cell 
infiltration [7]. However, a negative result in all of these parameters does not exclude 
BPS/IC. Occasionally, some patients do not exhibit abnormalities in the bladder, but 
they have other BPS/IC symptoms. So, it is important to exclude all other confoundable 
diseases, that could be the causes of the symptoms [5, 7, 22]. 
Furthermore, not all initial symptoms appear simultaneously but rather gradually 
[24]. In the early stage of the disease, symptoms may be mild and intermittent, but they 
tend to become constant and severe while the disease progresses [24]. Nocturia, for 
example, tends to appear later in the progress of the disease and, commonly, women 
report exacerbation of the symptoms during the premenstrual week [24]. Although the 
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median age of diagnosis of patients is 42-46 years old [24], the non-ulcer subtype of 
BPS/IC is usually associated with younger age at diagnosis [22]. 
 
1.4 Epidemiology of BPS/IC 
The prevalence of BPS/IC is difficult to estimate because of diagnosis 
demands. Hence, the available information about BPS/IC prevalence is based on 
different criteria. It is widely accepted that BPS/IC is more frequent in women than in 
men, with a female/male ratio that ranges from 5:1 to 10:1 [12, 25]. Also, some studies 
show that BPS/IC seems to be more frequent in Caucasians [7, 8, 10, 12, 24, 26]. 
However, one should not exclude that the cultural difference may reflect the different 
frequency observed in those studies.  Ito et al. say that BPS/IC is rare in Asian 
countries with an incidence of 2 per 100000 urological patients [7, 27]. On the other 
hand, the prevalence of BPS/IC in United States is 3-fold greater than the prevalence 
in Europe [28]. Looking at the overall population, Moutzouris et al. estimate a 
prevalence of 52 to 197 per 100000 women and 40 to 70 per 100000 men, diagnosed 
by a physician [24]. 
 
1.5 Treatment of BPS/IC 
Treatment of BPS/IC is not effective; it aims to reduce the symptoms and 
improve the patient´s quality of life, focusing in pain and urological symptoms 
(frequency and urgency). Presently, the most used treatments can be divided into four 
groups: conservative therapy, oral medication, intravesical therapy and interventional 
treatment and surgery [1, 2, 7, 11, 13, 18, 22, 26]. The conservative therapy includes 
alterations in the quotidian of patients diagnosed with BPS/IC to improve their life´s 
quality [1, 2, 7, 10, 22]. The oral medication includes a large variety of oral therapies, 
aiming at reducing symptoms. However, this type of treatments present reduced 
efficacy. Intravesical therapy consists on the application of a local anesthetic, alone or 
with other drugs, directly into the bladder. Interventional treatment for patients with 
BPS/IC include bladder distension, electromotive drug administration, transurethral 
resection, botulinum toxin A and hyperbaric oxygen. Surgery is only used as a last 
option [1, 2, 7, 10, 12, 14, 22].  
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2. Sympathetic nervous system dysfunction in BPS/IC 
  
 The relation between BPS/IC and the sympathetic nervous system was never 
evaluated. However, it is known that patients with BPS/IC present high levels of urinary 
catecholamines [29]. In 1999, Stein et al., showed that patients with BPS/IC have high 
levels of urinary catecholamines when compared to urine from normal volunteers [29], 
which may diffuse from sprouted sympathetic nerves in the mucosa and the detrusor, 
and may contribute to alterations in the permeability of the GAG-layer [23, 29, 30].  
Peeker and co-workers explored the neurogenic nature of BPS/IC, 
determining by immunohistochemistry the presence and density of nerve fibers 
containing tyrosine hydroxylase (TH, a sympathetic fibers marker) [12]. These authors 
observed that the number of TH immunoreactive fibers was significantly increased in 
BPS/IC patients when compared to control groups, suggesting an increase in the 
activity of the peripheral sympathetic nervous system, and therefore indicating a 
primary etiology [11, 12]. 
BPS/IC patients often exhibit an exaggerated response to stress, as observed 
in patients with anxiety disorders [30]. This can be related with dysfunction of the 
sympathetic nervous system [30, 31]. Furthermore, Charrua and co-workers 
demonstrated through the TILT test (tilt table test) that BPS/IC patients presented an 
increased sympathetic activity and confirmed an increase in noradrenaline levels in the 
urine of BPS/IC patients [9, 29, 30]. These observations presume overstimulation of 
adrenergic receptors present in the urinary bladder. The urinary bladder expresses 
different subtypes of α-adrenoceptors and β-adrenoceptors. The most abundantly 
expressed are the α1A, α1D and β3 subtypes. The α1A subtype is expressed in the 
bladder urothelium and body [32, 33]. Curiously, it is thought that the α1A adrenoceptor 
is activated only when an excess of norepinephrine exists in the urine or in the blood 
[32]. The α1D subtype is expressed in the detrusor muscle, in the urothelium, and has 
almost exclusively intracellular expression [32, 34, 35]. Both α- and β-adrenoceptors 
are involved in mediating the responses to the endogenous noradrenaline [36]. β3 
subtype is mainly expressed in the urothelium and when stimulated by mirabegron, a 
β3 –adrenoceptor agonist, it decreases detrusor contractility and the urinary frequency. 
So, the β3 subtype seems to not be involved in bladder pain or any change in bladder 
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morphology [36]. Therefore, the present study will focus on α-adrenoceptors, namely 
on α1A and α1D. 
  
2.1. Nociceptive pathway modulation by adrenoceptors 
 The overstimulation of adrenoceptors, in an animal model of rats chronically 
treated with phenylephrine, leads to pain, vesical hyperactivity, alterations in urothelium 
and mastocytosis, all signs and symptoms observed in patients with BPS/IC [30]. Pain 
and increased void frequency were dependent on capsaicin-sensitive primary afferents 
activation since desensitization of these fibers with high doses of capsaicin reverses 
the phenylephrine-mediated effects [37, 38], demonstrating a possible relation between 
the adrenergic and nociceptive activity. Hence, one of the aims of the present study is 
to demonstrate the involvement of adrenoceptors in the appearance of BPS/IC 
symptoms and that these receptors cross-talk with nociceptive receptors. In this study 
we will focus on TRPV1, a receptor expressed in afferent bladder nerves, forming a 
close contact with the bladder epithelium, in urothelial cells and in myofibroblasts [37, 
38, 39, 40]. It has been suggested that TRPV1 is overexpressed in the bladder of 
patients with BPS/IC [39, 41, 42]. Furthermore, it has been shown that the TRPV1 
receptor is essential for pain arousal and for an increase in bladder frequency during 
cystitis [43, 44]. 
 One possible mechanism through which the adrenoceptor could act over TRPV1 
is by an intracellular mechanism that will lead to its later sensitization. TRPV1 can be 
sensitized through phosphorylation by different kinases, such as protein kinase A 
(PKA), protein kinase C (PKC) and calmodulin-dependent kinase II (CaMKII), or by 
membrane lipids such as phosphothylinositol (4,5)-biphosphate (PIP2), which is 
cleaved by phospholipase (PLC) [45]. All these enzymes can be activated upon 
adrenoceptors stimulation.  
 Another possible mechanism is that adrenoceptor activity can indirectly modulate 
TRPV1 activity by acting on other receptors. Cannabinoid receptors are one example 
[46]. The expression of cannabinoid receptor 1 (CB1), which co-localizes with TRPV1, 
increases in patients with chronic bladder pain syndromes [47]. Furthermore, systemic 
administration of cannabinoid agonists reduced pain induced by bladder inflammation 
and increased the voiding interval [47], a mechanism that involves inhibition of bladder 
afferent nerves [48]. TRPV1 and CB1 have common agonists, such as anandamide 
[46, 49]. Anandamide is a lipid, which is an endocannabinoid, and can have analgesic 
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effects in animal models of inflammatory pain [49, 50]. Anandamide can be degraded 
by FAAH (fatty acid amide hydrolase), an enzyme present in the human and rat 
urothelium [50, 51, 52]. It is thought that when administrated at low doses, anandamide 
acts on CB1, but at high doses, anandamide acts on TRPV1 [46, 47]. Although the 
inhibition of FAAH by URB597, an inhibitor of FAAH, has been referred to suppress 
peripheral hyperalgesia induced by bladder inflammation [50], no studies have been 
conducted in BPS/IC. 
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II. Aims 
 
This work has three main goals: 
 
The first goal is to demonstrate the involvement of adrenoceptors in the 
appearance of BPS/IC symptoms, by characterizing the adrenoceptors subtypes 
involved in the appearance of pain and organ motility changes and by characterizing 
which adrenoceptor subtypes are involved in the bladder histological changes 
observed in rats submitted to chronic adrenergic stimulation. 
 
The second aim is to evaluate the cross-talk between adrenoceptors and 
TRPV1 during chronic adrenergic stimulation. 
 
The third aim is to understand how endocannabinoids modulate bladder pain 
and hyperactivity during cystitis. 
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III. Material and Methods 
 
1. Experimental Animals 
Adult female Wistar rats (175-200g) and adult C57BL/6J mice (20-25g) were 
bought from Charles River Laboratories (Barcelona, Spain). TRPV1 Knockout (KO) 
mice (20-25g) were bought from Jackson Laboratories (Bar Harbor, Maine, USA). All 
animals were maintained at 22 ᵒC, with 60% humidity, under inverted light-dark cycle 
(12h/12h), and provided with water and food ad libitum. All experiments were 
performed according to the European Communities Council Directive of 24 November 
1986 (86/609/EEC), after approval from Ethical Committee of the Faculty of Medicine 
of University of Porto and from Direcção Geral de Alimentação e Veterinária. 
 
2. Chronic adrenergic stimulation 
 Chronic adrenergic stimulation was induced in mice and rats, by performing 
daily subcutaneous injections, for 14 days, with 2.5 mg phenylephrine (PHE)/Kg body 
weight (Sigma-Aldrich). 
 
2.1. Blockade of alpha1-adrenoceptors 
For α1-adrenoceptor subtype blockade, rats orally received specific α1-
adrenoceptor subtypes antagonists, concomitantly with the daily chronic adrenergic 
stimulation (n=6 for each group) (see table 1). Rats receiving vehicle were used as 
negative controls (group A). Rats receiving phenylephrine were used as positive control 
(group B) (see attachment 1). 
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Table 1. Experimental groups of Wistar rats submitted to chronic adrenergic stimulation and alpha-adrenoceptors antagonists. 
Group Treatment Dose 
C α1A-AR antagonista (Silodosin (Urorec®, Recordati) 0.2 mg/ Kg 
D α1D-AR antagonist (Naftopidi, *) 0.9375 mg/ Kg 
E α1-AR antagonist (Prazosin, Sigma-Aldrich) 0.05 mg/ Kg 
*Naftopidil was a kind gift from Prof. Igawa from Department of Continence Medicine, University of Tokyo, Tokyo, Japan 
 
2.1.1. Pain behavior test 
 Visceral pain behavior tests were performed before and 14 days after beginning 
the treatment, in all animals from all groups and treatments used. 
Visceral pain behavior was evaluated using a mechanical hyperalgesia test, 
adapted from Laird et al., 2001 [53]. Animals were placed in individual chambers (230x 
170x 140 mm) with a wire mesh floor and allowed to acclimate for 20 min or until cage 
exploration stopped (Figure 2a). This test was performed in the lower abdominal 
region, and consists in touching this region with one of a series of Von Frey 
monofilaments (rated at 4, 6, 8, 10, 15, 26 and 60g for rats, or rated 0.008, 0.02, 0.04, 
0.07 and 0.16g for mice). Filaments were applied 5 seconds perpendicularly with 
enough strength to cause the monofilament to slightly bend (see figure 2b). Each 
monofilament was tested 5 times with an interval of 30 seconds between 
monofilaments. It was considered a positive response when the animal reacted to the 
filament (abdomen retraction or jump) in at least three of the five filament applications. 
In case of no response to the filament, the next-stronger monofilament was applied. 
Figure 2. Animals placed in individual chambers to perform visceral pain behavior test (figure 2a), in the lower abdominal region 
using a series of Von Frey monofilaments (figure 2b), according to Laird et al., 2001 [53]. 
 
 
A 
B 
B 
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2.1.2. Organ motility test 
Organ motility tests were also assessed before and 14 days after beginning the 
treatment, in all animals from all groups and treatments used. 
Urinary spots were used to analyze voiding frequency (urinary spots/ h). For 
this, the animals were placed in boxes with filter paper during one hour (figure 3). 
 
Figure 3. Animals placed into boxes with filter paper to analyze alterations on bladder motility. 
 
2.1.3.  Cystometry  
 In animals submitted to chronic adrenergic stimulation with PHE, cystometries 
were performed at day 15 after beginning the treatment with PHE alone or with each 
antagonist of α1-adrenoceptor subtypes, under anesthesia with urethane (1.2 g/ Kg 
body weight, subcutaneously), with the body temperature maintained at 37ᵒC with a 
heating pad. The bladder dome was exposed through a small, low abdominal incision. 
A 20 gauge needle was inserted in the bladder dome and saline solution was infused 
(6 mL/ h) (figure 4).  After a period of 30 minutes of stabilization, the infusion of saline 
solution was recorded for 2 hours, to analyze bladder reflex activity (number of bladder 
contractions/ minute).  
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Figure 4. Animals under cystometry, over a heating pad and with a 20 gauge needle inserted in the bladder dome to infuse a saline 
solution. 
 
 
2.1.4. Tissue harvesting and processing 
Two hours after the beginning of cystometry, animals were transcardially 
perfused with Tyrode´s solution followed by paraformaldehyde 4% (see attachment 2). 
L6 spinal cord segments were harvested and sectioned at 40 µm. The urinary bladders 
were harvested, fixed by immersion in 10% buffered formalin, for 24 hours, embedded 
in paraffin, sectioned at 10-12 µm and mounted on poly-L-lysine-coated slip.  
 
2.1.5. Immunohistochemistry 
L6 spinal cord segments were sectioned and immunoreacted against Fos 
protein, a pain and neuronal activity marker (see attachment 3 and 5 for a more 
detailed protocol). The number of Fos immunopositive cells were determined under the 
light microscopy Zeiss Axioskop 40. 
Bladder sections were immunoreacted against caspase 3, a marker of cellular 
apoptosis, to analyze urothelium integrity (see attachment 4 and 5 for a more detailed 
protocol). Slides were observed under fluorescence microscope Zeiss Apotome and 
images were acquired.  
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2.1.6. Bladder Histological Evaluation 
To assess urothelium integrity, bladder sections were stained for Hematoxylin-
Eosin (see attachment 6 for a more detailed protocol) and the thickness of the 
urothelium and the extension of lesion was determined using AxioVision 4.0. 
 To analyze mast cell infiltration, bladder sections were stained with Toluidine 
Blue (see attachment 7 for a more detailed protocol). Images were acquired and the 
number of mast cells was counted. Bladder mucosa areas were determined using 
ImageJ 1.47v software. 
 
2.2  Cross-talk between adrenoceptors and TRPV1 
To evaluate the cross-talk between α-adrenoceptor and TRPV1, TRPV1 
knockout mice (n=6) were submitted to chronic adrenergic stimulation with 
phenylephrine for 14 days. Furthermore, a control group with wild type mice injected 
with saline solution and a group of wild type mice injected with phenylephrine were 
used (n=6 for each group). Pain behavioral tests (as described in 2.1.1) were 
performed. 
To verify if chronic adrenergic stimulation enhances TRPV1 response, adult 
female Wistar rats (n=6) were submitted to chronic adrenergic stimulation with 
phenylephrine daily for 14 days. At the end of treatment, animals were submitted to a 
cystometry (as described in 2.1.3). After saline infusion, 50µM capsaicin (TRPV1 
agonist, Sigma-Aldrich) was infused. This procedure was repeated in another group of 
four animals injected with saline, used as control group (n=4). 
 
3. Cannabinoid system and TRPV1 cross-talk during cystitis 
 
3.1  LPS-induced cystitis 
 Cystitis was induced by intravesical instillation of 0.5 mL of lipopolysaccharide 
(LPS, Sigma-Aldrich) 5 mg/ mL, for 1h, in female Wistar rats (n=6 for each drug 
application). Control animals were instilled with saline solution (n=6). 
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3.2  Pain behavior test 
Visceral pain behavior tests (as described in 2.1.1) were performed before 
inflammation, 24h after LPS instillation and after 1 µM URB937 injection. 
 
3.3  Cystometries 
 Twenty-four hours after LPS or saline instillation (n=6 for each drug application), 
cystometry was performed as described in 2.1.3.  After a period of 30 minutes of 
stabilization, URB397 (Cayman Chemical Company) was given intravenously in doses 
of 0.01, 0.1, 1, 5 and 10 µM (cumulative doses) to LPS- and saline-treated animals.  
Since the dose most effective to reduce bladder reflex activity induced by 
cystitis was 1µM of URB, it was used 1µM of URB937 + 10 µM MJ15 (CB1 antagonist, 
Tocris Bioscience), 1µM URB937 + 0.3 mg/ Kg SR144528 (CB2 antagonist, Cayman 
Chemical Company) to determine the involvement of each cannabinoid receptor in 
FAAH induced blockade. 
Since 7 mg/kg induced bladder hyperactivity, 1µM URB937 + 1.4 µg/ Kg 
SB366791 (TRPV1 antagonist, Tocris Bioscience) were used to analyze the 
involvement of TRPV1.  
At the end of the cystometry, bladders were harvested and the cystitis was 
confirmed histologically. 
 
4. Data presentation 
 Data are presented as mean ± standard deviation and comparison between the 
paired data were performed by using the Student´s t test. For multiple comparisons, the 
statistical analysis was performed using the Dunn’s Multiple Comparisons Test 
(ANOVA – One-way analysis of variance non-parametric). P values inferior to 0.05 
were considered statistically significant. 
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IV. Results 
 
 
1. Blockade of alpha1-adrenoceptors 
 
 
1.1 Pain behavior test 
 Control animals presented a score of 41.2 ± 21. It was observed that animals 
treated with PHE had a decreased mechanical pain threshold compared with the 
control, with a score of 6.7 ± 2.4 (P<0.001, figure 5). The blockade with Silodosin or 
Prazosin reversed the effect of PHE to 20.8 ± 19.3 and 14.2 ±7.0, respectively. 
Naftopidil was unable to reverse PHE induced referred pain, 6.0 ± 2.5 (P<0.001, figure 
5). 
  
Figure 5. Graph bar showing lower abdominal mechanical pain threshold using Von Frey filaments. After chronic adrenergic 
stimulation with 2.5 mg of PHE/kg body weight, animals presented a decrease in the mechanical pain threshold (*** P < 0.001 
comparing to control). Co-treatment with silodosin and prazosin abolished abdominal mechanical pain threshold. Naftopidil was 
unable to reverse PHE effect (*** P<0.001).The statistical analysis were performed using the Dunn’s Multiple Comparisons Test 
(ANOVA – One-way analysis of variance non-parametric). 
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1.2 Organ motility test  
 Control animals had 2.8 ± 1.0 urinary spots/ h. PHE treatment induced an 
increase in the number of urinary spots/ h to 7.8 ± 3.3, when compared to control group 
(P<0.05, figure 6). In animals submitted to treatment with PHE concomitantly with 
Silodosin or Prazosin the number of urinary spots/ h is similar to control animals, 4.8 ± 
3.3 and 4.3 ± 4.6 urinary spots/h, respectively (figure 6). Animals  treated with Naftopidil 
had an increase in the number of urinary spots/h to 9.2 ± 2.6 (P<0.01) (figure 6). 
 
Figure 6. Graph bar showing the voiding frequency (urinary spots/ h) of control animals, animals submitted to chronic adrenergic 
stimulation with PHE (PHE group) and animals submitted to chronic adrenergic stimulation with PHE and α-adrenoceptors 
antagonist (group PHE+ Silodosin, PHE+ Naftopidil and PHE+ Prazosin).  The statistical analysis were performed using the 
Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-parametric). 
 
1.3 Cystometry  
 Control animals had 0.4 ± 0.1 bladder contractions/ min. PHE treated animals 
had an increased bladder reflex activity, reading values of 1.9 ± 0.9 bladder 
contractions/min (P<0.001, figure 7). Adrenoceptors antagonists Silodosin or Prazosin 
were able to reverse PHE-induced bladder reflex activity to values of 0.7 ± 0.2 and 0.7 
± 0.2 bladder contractions/ min, respectively (figure 7). Co-treatment with Naftopidil 
also increased bladder reflex activity to 1.9 ± 0.4 bladder contractions/ min (P<0.001) 
(figure 7). 
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Figure 7. Graph bar showing the bladder reflex activity (bladder contractions/ minute) of control animals, animals submitted to 
chronic adrenergic stimulation with PHE (PHE group) and animals submitted to chronic adrenergic stimulation with PHE and α-
adrenoceptors antagonist (group PHE+ Silodosin, PHE+ Naftopidil and PHE+ Prazosin). The statistical analysis were performed 
using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-parametric). 
 
 
1.4  Immunohistochemistry 
The L6 spinal cord segment of control animals had 5 ± 3 immunopositive cells. 
PHE treated animals had an increase in the number of Fos immunopositive cells/ 
section to 33 ± 6 (P<0.01, figure 8). The blockade with Silodosin or Prazosin reverses 
the effect induced by PHE to 8 ± 3 and 4 ± 0.5, respectively. Blockade with Naftopidil 
also increased the number of Fos immunoreactive cells for 21 ± 7 (P<0.05) (figure 8). 
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Figure 8. Graph bar showing the spinal Fos expression (number of Fos immunopositive cells/ section). Chronic adrenergic 
stimulation with 2.5 mg PHE/ kg body weight, increase the number of Fos immunopositive cells/ section (** P<0.01).Co-treatment 
with Silodosin or Prazosin reverse the effect induced by PHE. Treatment with Naftopidil also increase spinal Fos expression. The 
statistical analysis were performed using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-
parametric). 
. 
 
Bladder sections from control animals showed no staining for caspase 3 (figure 
9A). The bladder of animals that received chronic adrenergic stimulation presented 
caspase 3 staining in the urothelium (figure 9B). Naftopidil induced cellular apoptosis, 
as observed by caspase 3 staining (figure 9D). Bladder of animals that received 
Silodosin or Prazosin, were not stained for caspase 3 (figure 9C and 9E, respectively).  
    
                 
Figure 9. Bladder sections immunoreacted against caspase 3. A) control group. B) PHE group. C) PHE and Silodosin. D) PHE and 
Naftopidil. E) PHE and Prazosin. 
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1.5 Bladder histological evaluation 
Bladder sections from controls stained for Hematoxylin-Eosin exhibited an 
urothelium without disruption.  Treatment with PHE and antagonists (Naftopidil or 
Prazosin) increased the percentage of low urothelium to 53% ± 15, 82% ± 14 and 
46.9% ± 17,7, respectively (P<0.001, figure 10). Adrenoceptor antagonist Silodosin 
reversed the effect of PHE for 12% ± 13 (figure 10). 
 
 
Figure 10. Graph bar showing the urothelium integrity (percentage of low urothelium) of bladder sections stained with 
Hematoxylin-Eosin. PHE, PHE +Naftopidil and PHE +Prazosin increase the percentage of low urothelium (*** P<0.001). 
Administration of Silodosin or Silodosin + Naftopidil reverses the effect induced by PHE. The statistical analysis were performed 
using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-parametric). 
 
 Bladder sections from control animals stained for Toluidine Blues presented 8 ± 
4 mast cells/ mm2 (figure 11). Treatment with PHE increased the number of mast cells 
in mucosa layer to 17 ± 6 (P<0.05, figure 11). Co-administration of PHE and Naftopidil 
also increased the number of mast cells/ mm2 to 20 ± 5 (P<0.01, figure 11). 
Adrenoceptors antagonists Silodosin or Prazosin reversed the effect of PHE to values 
of 14 ± 4 and 16 ± 8, respectively (figure 11).  
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Figure 11. Graph bar showing the mast cells (mast cells/ mm2) in bladder sections stained with Toluidine Blue. PHE increase the 
number of mast cells (* P<0.05).Co-treatment with Naftopidil also increase the number of mast cells (** P< 0.01). Administration 
of Silodosin or Prazosin reverses the effect induced by PHE. The statistical analysis were performed using the Dunn’s Multiple 
Comparisons Test (ANOVA – One-way analysis of variance non-parametric). 
 
2. Cross-talk between adrenoceptors and TRPV1 
 
2.1 Pain behavior test 
 Control animals (WT saline) had a score of 0.09 ± 0.06 (figure 12). Chronic 
adrenergic stimulation in wild type animals decreased mechanical pain threshold 
compared to control to 0.008 ± 0.0 (P<0.05, figure 12). Administration of PHE to 
knockout (KO) TRPV1 animals increased the pain threshold to values similar to those 
of the control group (figure 12). 
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Figure 12. Graph bar showing lower abdominal mechanical pain threshold using Von Frey filaments. PHE administration to WT 
animals decrease pain threshold (*P<0.05). The statistical analysis were performed using the Dunn’s Multiple Comparisons Test 
(ANOVA – One-way analysis of variance non-parametric). 
 
2.2  Cystometry  
Control animals under cystometry presented a value of 0.58 ± 0.21 bladder 
contractions/ minute. Administration of 50 µM of capsaicin to these animals increased 
the number of bladder contractions to 0.90 ± 0.18, presenting a variation of 0.33 ± 0.15 
(figure 13). Animals treated with PHE had 1.73 ± 1.02 bladder contractions/ minute 
(figure 13). Capsaicin administration increased the number of bladder contractions to 
2.68 ± 1.28, when compared to animals treated with PHE (figure 13), presenting a 
variation of 0.95 ±0.37 (figure 13). 
 
  
Figure 13. Graph bar of bladder reflex activity (bladder contractions/ minute) evaluated during cystometry with saline and capsaicin 
(CAP) in control Wistar rats and in female Wistar rats submitted to chronic adrenergic stimulation with PHE. 
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3. Cannabinoid system and TRPV1 cross-talk during cystitis 
 
3.1 Cystometries  
 
Control animals presented 0.5 ± 0.1 bladder contractions/ minute. Animals with 
cystitis presented an increase in the number of bladder contractions/ minute to 2.1 ± 
0.6 (figure 14). 1µM of URB937 reversed the bladder hyperactivity (0.7 ± 0.2 bladder 
contractions/ minute in LPS-treated animals, figure 14). 5 µM and 10 µM of URB937 
increased bladder hyperactivity (1.3 ± 0.4 and 2.4 ± 0.8 bladder contractions/ minute, 
respectively, in LPS-treated animals, figure 14).   
  
 
 
Figure 14. Line graph of bladder reflex activity of control animals and LPS-treated animals submitted to different concentrations of 
URB937. 
 
 
Control animals instilled with vehicle had 0.5 ± 0.1 bladder contractions/ minute. 
Administration of URB937 1µM alone or concomitantly with CB2 antagonist SR144528 
to control animals did not change the bladder reflex activity (0.5 ± 0.2 and 0.4 ± 0.1, 
respectively, figure 15).  
Animals with cystitis (n=6) had 0.9 ± 0.1 bladder contractions/ minute. 
Administration of URB937 alone or co-administrated with CB2 antagonist SR144528 in 
these animals did not change significantly the number of bladder contractions (0.7 ± 
0.2 and 0.55 ± 0.07, respectively) (figure 15).  
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Figure 15. Graph bar of bladder reflex activity of control animals and LPS-treated animals submitted to URB937 and SR144528 
(CB2 antagonist). Administration of URB937 alone or with CB2 antagonist decrease the number of bladder contractions/ minute. 
The statistical analysis were performed using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-
parametric). 
 
 
Control animals instilled with vehicle had 0.5 ± 0.1 bladder contractions/ minute 
(figure 16). Administration of URB937 1µM alone or concomitantly with CB1 antagonist 
MJ15 to these animals did not change the bladder reflex activity (0.5 ± 0.2 and 0.6 ± 
0.2, respectively, figure 16).  
Animals with cystitis (n=6) had 1.42 ± 0.23 bladder contractions/ minute 
(P<0.001 compared to control). Administration of URB937 in these animals decreased 
the number of bladder contractions to 0.7 ± 0.2 (figure 16). Animals administrated with 
URB and the CB1 antagonist (MJ15) had an increase in bladder reflex activity to 1.9 ± 
0.8 (P<0.01) compared with LPS-inflamed animals instilled with vehicle (figure 16).  
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Figure 16. Graph bar of bladder reflex activity of control animals and LPS-inflamed animals submitted to URB937 and MJ15 (CB1 
antagonist). LPS-inflamed animals have an increase in the number of bladder contractions, when compared to control (*** 
P<0.001). Administration of URB937 in LPS-inflamed animals reduces the number of bladder contractions/ minute. Co-
administration of URB937 and CB1 antagonist increase bladder reflex activity (** P<0.01). The statistical analysis were performed 
using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-parametric). 
 
 
 
Control animals (n=3) instilled with vehicle had 0.4 ± 0.2 bladder contractions/ 
minute (figure 17). Administration of URB937 1 µM alone or concomitantly with TRPV1 
antagonist SB366791 did not change the bladder reflex activity (0.4 ± 0.2 and 0.4 ± 0.2, 
respectively, figure 17).  
Animals instilled with LPS (n=3) and vehicle had 1.2 ± 0.2 bladder contractions/ 
minute. Administration of URB937 on animals with cystitis increased the number of 
bladder contractions to 2.4 ± 0.8 (figure 17). Co-administration of URB937 and TRPV1 
antagonist SB366791 in LPS-inflamed animals decreased the number of bladder 
contractions/ minute to 1.3 ± 0.6 (figure 17). 
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Figure 17. Line graph of bladder reflex activity of control animals and LPS-inflamed animals submitted to URB937 and SB366791 
(TRPV1 antagonist). Administration of URB937 in LPS-inflamed animals increases the number of bladder contractions/ minute. 
Co-administration of URB937 and TRPV1 antagonist in LPS-inflamed animals decrease the number of bladder contractions/ 
minute. The statistical analysis were performed using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of 
variance non-parametric). 
 
 
 
3.2 Pain behavior test 
Control animals presented a score of 18 ± 7. Animals with cystitis had a 
decreased mechanical pain threshold compared with the control, with values of 1 ± 1 
(P<0.001, figure 18). Administration of 1µM of URB937 increased the pain threshold to 
7 ± 3 (figure 18), when compared to control group. 
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Figure 18. Graph bar showing lower abdominal mechanical pain threshold using Von Frey filaments. Instillation of LPS decreases 
the pain score (*** P<0.001). Administration of URB937 increased pain threshold. The statistical analysis were performed using the 
Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of variance non-parametric). 
 
 
 
3.3 Immunohistochemistry  
Control animals had 5 ± 3 Fos immunopositive cells/ section (figure 19). 
Instillation of LPS increased the number of Fos immunopositive cells/ section to 31 ± 
12 (P<0.01, figure 19).  
Animals instilled with LPS and administrated with URB937 had a decrease in 
the number of Fos immunopositive cells/ section to 15 ± 8 (P<0.05, figure 19). 
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Figure 19. Graph bar of expression of Fos protein in control animals, LPS-inflamed animals and in LPS+1µM URB937. Instillation 
of LPS increase the number of Fos immunopositive cells, when compared to control (** P<0.01). Animals instilled with LPS and 
administrated with URB937 had a decrease in the number of Fos immunopositive cells, when compared to LPS-inflamed animals (* 
P<0.05). The statistical analysis were performed using the Dunn’s Multiple Comparisons Test (ANOVA – One-way analysis of 
variance non-parametric). 
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V. Discussion 
 
 
The major outcomes of the present work were: 
 
1. Alpha1A-adrenoceptors mediate pain induced by chronic adrenergic 
stimulation; 
 
2. Chronic adrenergic stimulation-mediated effects occur through a TRPV1-
dependent mechanism, which involves the receptor sensitization; 
 
3. Endocannabinoids modulate visceral pain and bladder activity, through CB1 
and TRPV1 receptor, during cystitis. 
 
 
1. Alpha1A-adrenoceptors mediate pain induced by chronic adrenergic 
stimulation 
 
The present experiments confirm that chronic adrenergic stimulation with PHE 
induces visceral pain behavior in animals and bladder hyperactivity, which are a 
characteristic exhibited by BPS/IC patients [30]. Administration of PHE and Silodosin 
(α1A-adrenoceptor antagonist) reversed visceral pain behavior and reversed the 
bladder hyperactivity induced by PHE. It is known that urinary bladder express alpha-
adrenoceptors [54, 55, 56, 57, 58, 59]. The α1-adrenoceptors can be found throughout 
the urinary bladder [34, 35, 60]. In the bladder of healthy individuals, there is no 
evidence of an outstanding alpha-adrenergic stimulation. However, under pathologic 
conditions, it is known that there is an increase in the density of α-adrenoceptors, 
insomuch, that the noradrenaline-induced response in the bladder is converted from 
relaxation to contraction [54], which can contribute to the bladder hyperactivity 
observed in some disorders like BPS/IC. 
In the present work, the animals under chronic adrenergic stimulation also 
presented an increase in spinal Fos protein expression, indicating that PHE induces 
activation of nociceptive pathways coming from the bladder. Patients with BPS/IC 
present an increase both in nociceptive fibers containing substance P (SP) and in 
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urinary substance P [2, 61, 62]. This increase has a positive correlation with the 
severity of pain felt by those patients [2]. The reduction of Fos expression by the 
blockade of α1A-adrenoceptor suggest that this receptor alters the activity of primary 
afferents. Its blockade may lead to a decrease the transmission of nociceptive 
information to central nervous system, which could result in a decrease in pain and 
vesical activity.  
Chronic adrenergic stimulation with PHE induced mast cell infiltration, a sign 
similar to the one observed in patients with BPS/IC [1, 2, 6, 9, 26]. This could be a 
consequence of nociceptive fibers activation since the release of SP is known to cause 
degranulation and activation of mast cells present nearby nerve terminals [2]. The 
blockade of α1A-adrenoceptor inhibited mast cell migration induced by mast cell 
activation, showing that this receptor is somehow involved in the chemotaxis of these 
inflammatory cells. Hence, α1A-adrenoceptor blockers present themselves as good 
targets to overcome pain and inflammation associated with BPS/IC. 
Chronic adrenergic stimulation also induced urothelium disruption as observed 
by an increase in the percentage of degraded urothelium and the immunoreactivity for 
the pro-apoptotic molecule caspase 3. Patients with BPS/IC exhibit disruption in the 
urothelium similar to the ones observed in the present work [1, 2, 6, 9, 23]. In fact, it 
was observed that the urothelium from BPS/IC patients was immunopositive for 
caspase 3 [63, 64]. Charrua et al. has observed that the urothelium from animals 
submitted to chronic adrenergic stimulation with PHE was immunopositive for caspase 
3 [30]. The blockade of α1A-adrenoceptor reversed the urothelium damage induced by 
PHE, possible by blocking apoptosis, showing that this effect resulted from adrenergic 
overactivity. The urothelium has a barrier function, to prevent the diffusion of urine 
constituents for the underlying tissues [14, 65]. Urothelial damage allows the diffusion 
of urinary solutes which may activate sensory nerve endings, leading to pain, 
inflammation and urinary frequency. Hence, the reversion of urothelium damage will 
possible contributes to an improvement of all other symptoms observed in BPS/IC 
patients. In fact, patients that receive pentosan polysulfate sodium, known to decrease 
the permeability of urothelium, reported an improvement of pain, urgency and 
frequency [1, 7, 13, 18, 22]. 
Chronic adrenergic stimulation with phenylephrine increased bladder reflex 
activity, as previous demonstrated by Charrua et al. [30]. The increase in bladder reflex 
activity can be translated as an increase in the number of bladder contraction per 
minute, which means that the urinary frequency increases. This increase in urinary 
frequency is also reported in patients with BPS/IC [1, 2, 4, 22]. The blockade of α1A-
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adrenoceptor reverses the increase in bladder reflex activity, which means that, under 
pathologic conditions, this receptor is involved in the increase of urinary frequency.  
 
 
2. Chronic adrenergic stimulation-mediated effects occur through a TRPV1-
dependent mechanism, which involves the receptor sensitization 
 
Pain and increased frequency were dependent of capsaicin sensitive primary 
afferents activation since desensitization of these fibers with capsaicin reverses the 
phenylephrine mediated effect [40, 41]. These results indicate that there is relation 
between adrenergic activity and nociceptive activity. TRPV1 has been shown to be 
essential for the development of bladder pain and hyperactivity during cystitis [38, 43, 
46] being the urinary bladder nociceptive receptor per excellence [37, 38, 39, 63]. In 
fact, TRPV1 is overexpressed in the urinary bladder of patients with BPS/IC [39, 41, 
42]. 
Hence, in this work it was hypothesized that adrenoceptors interact with TRPV1 
inducing the PHE-mediated effects. In fact, TRPV1 knockout mice chronically treated 
with PHE did not feel pain nor presented any of the bladder changes observed in their 
wild type littermates. These results show that TRPV1 activity is downstream to α-
adrenoceptors activation.  
It was also hypothesized that adrenoceptor sensitized TRPV1 by an intracellular 
mechanism. In the present work it was observed that PHE-treated animals had higher 
bladder frequency upon capsaicin stimulation than control animals. This seems to point 
to a sensitization of TRPV1. In fact, α-adrenoceptors activation is known to trigger the 
Gq/11 signaling pathway, therefore promoting the activation of phospholipase C (PLC), 
phospholipase A2 (PLA2) and phospholipase D (PLD) [37, 38]. In turn, these enzymes 
lead to mobilization of Ca2+ from intracellular stores and activation of mitogen-activated 
kinase and phosphathylinositol (4,5)-biphosphate (PIP2) kinase pathways, which 
causes vasoconstriction. The influx of calcium and the consequential increase of 
intracellular calcium concentration are necessary for the desensitization of TRPV1.  
Many signaling pathways, like calmodulin (CaM) and the decrease of PIP2, are 
implicated in desensitization of TRPV1 [37, 66]. The process of sensitization of TRPV1 
is made by phosphorylation, by different kinases, like protein kinase A (PKA), protein 
kinase C (PKC) and calmodulin-dependent kinase II (CaMKII), or by membrane lipids 
such as PIP2, which is cleaved by phospholipase (PLC). It is known that TRPV1 needs 
to be phosphorylated by CaMKII to be activated by vanilloids [67]. All these enzymes 
are known to sensitize TRPV1 [68]. 
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3. Endocannabinoids modulate visceral pain and bladder activity, through CB1 
and TRPV1 receptor, during cystitis 
The administration of URB937 did not produce any effect on the bladder 
frequency nor pain behavior of control animals. Furthermore, administration of URB937 
concomitantly with exogenous cannabinoids, such as SR144528, MJ15 or SB366791, 
also did not produce any effect on bladder frequency.  
The administration of 1 mM URB937 to animals with cystitis reversed bladder 
hyperactivity. However, at doses of 5 and 10 mM URB937 induced an increase of 
bladder frequency. FAAH blockade increases endocannabinoids levels [49].  
Anandamide (AEA) is one of those molecules. AEA is known to act both in CB1 and 
TRPV1 receptors, which are co-expressed in most nociceptive primary sensory 
neurons in bladder [46, 47].  
In fact, previous work has demonstrated that anandamide could contribute to 
the development of hyperalgesia and hyperreflexia by activating TRPV1 [46]. Hence, it 
was hypothesized that when low doses of URB are used, endocannabinoids levels may 
reach a plateau that lead to CB1 activation. Increasing endocannabinoids levels by 
further blocking FAAH, they will act on TRPV1. In fact, the reversion of 1 mM URB 
effect by blocking CB1 receptor demonstrated the involvement of this receptor. 
It is known that administration of cannabinoid agonists reduce pain induced by 
bladder inflammation [47]. In this work, FAAH inhibition reversed bladder pain induced 
by inflammation. This result is corroborated by a decrease in Fos expression at L6 
spinal cord level after URB937 application. Altogether these results suggest that FAAH 
inhibition and, subsequently, endocannabinoids are involved in the activation of 
nociceptive pathways.  
 
 
In summary, it is possible that during bladder painful syndrome/ interstitial 
cystitis there is an interaction between several pathways, namely α1A-adrenoceptors, 
TRPV1 and CB1, as shown in the following schematic drawing: 
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VI. Conclusion 
 
 The present work confirmed that chronic adrenergic stimulation with 
phenylephrine induces visceral pain, mast cell infiltration, apoptosis of urothelial cells 
and activation of nociceptive pathways. Silodosin (antagonist of α1A-adrenoceptor 
subtype) seems to be more effective than naftopidil or prazosin (α1D and α1-
adrenoceptor antagonist) to reduce the effects induced by chronic adrenergic 
stimulation with phenylephrine. 
 According to previous studies, this work showed that TRPV1 are involved in 
bladder hyperactivity, as well as CB1. However, it is necessary more studies to better 
understand the role of these receptors in bladder hyperactivity, a characteristic of 
BPS/IC. 
 Thus, we can conclude that BPS/IC results from the activation and the cross-
talk between different pathways, possibly involving α-adrenoceptors, TRP channels 
(TRPV1 and possibly TRPV4) and cannabinoid receptors (CB1). 
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VII. Future work 
  
 This work allows characterizing the adrenoceptors subtypes involved in pain, 
organ motility and bladder histological changes in an animal model of BPS/IC. These 
results suggest that silodosin (antagonist of α1A-adrenoceptor subtype) seems to be 
more effective to reduce the effects induced by chronic adrenergic stimulation with 
phenylephrine. Furthermore, BPS/IC seems to be a result of the cross-talk between 
different pathways, involving α-adrenoceptors, TRPV1 and cannabinoid receptors 
(CB1). However the role of these receptors in bladder hyperactivity is not completely 
understood. 
 
 Besides TRPV1 and CB1, there are more nociceptive receptors such as P2X3, 
which could be also involved in bladder hyperactivity [69]. Activation of P2X3 and TRP 
channels by bladder distension or chemical stimuli can release some mediators like 
ATP, Ach (acetylcholine) and NGF (nerve growth factor) [70]. It is also known that 
patients with BPS/IC present altered levels of APF (anti-proliferative factor), NGF, 
BDNF (brain derived nerve factor), and interleukins, among others [71]. 
 
 Some authors, observed a decrease in the microvascular density in the 
suburothelium in patients with BPS/IC, suggesting that hypoxia can be a cause of the 
disease [1, 25]. To clarify this idea, would be interesting to study the effect of chronic 
bladder ischemia in bladder function and morphology and in sympathetic activity, using 
a rat model of atherosclerosis-induced chronic bladder ischemia. 
 
  
 Thus, there are many questions that can be studied in a future work. Which are 
the connections between the adrenoceptor pathways and the nociceptive pathways, 
namely at the expression and function of TRP (TRPV1 and TRPV4) receptors? What 
are the roles of CB1 and P2X3 in this process? Will NGF, BDNF and interleukins be 
involved in BPS/IC? How ischemia influences BPS/IC characteristics? Can ischemia 
stimulus induce sympathetic overactivity and how these can induce the changes 
observed in patients with BPS/IC? 
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The role of TRPV4 and P2X3 can be assessed using PHE-treated animals 
administrated with agonists and antagonists of these receptors and using co-cultures of 
DRG and urothelial cells treated with PHE. The activity of these receptors can be 
determined by calcium imaging technique.   
To assess the role of neurothrophins and interleukins, control animals and 
ovariectomized animals can be submitted to chronic adrenergic stimulation with PHE 
for 14 days. Urine samples can be collected before, at day 8 and day 14 after 
beginning the treatment, to determine neurothrophins and interleukins levels by ELISA. 
The levels of neurothrophins and interleukins can also be determined in urine from 
BPS/IC patients and aged matched normal volunteers. 
 To verify if an ischemic stimulus induces chronic sympathetic overactivity and 
verify whether this sympathetic overactivity induces bladder changes observed in 
BPS/IC patients, that an animal model of atherosclerosis-induced chronic bladder 
ischemia, like described by Nomiya et al., 2012 [72], can be used. 
 After ischemic insult and at different time points, the levels of plasmatic and 
urine noradrenaline can be measured by ELISA and HPLC. Organ expression of 
tyrosine hydroxylase and dopamine-β-hydroxylase, by immunohistochemistry and 
western blot, respectively, can be also assessed. Furthermore, visceral pain behavior 
and organ motility and integrity can be evaluated at different point times, as well as 
spinal Fos expression and inflammatory signs. 
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IX.  Attachments 
 
1. Phenylephrine and antagonist solutions 
 
The phenylephrine (Sigma-Aldrich P6126-5G) solution used for chronic 
adrenergic stimulation both in rat and mice was daily injected at 2.5 mg/ Kg body 
weight. This solution vehicle was saline solution. 
Silodosin (antagonist of alpha1A- adrenoceptor) were used in a concentration of 
0.2 mg/ Kg. Naftopidil (antagonist of alpha1D- adrenoceptor) were used in a 
concentration of 0.9375 mg/ Kg. The solution vehicle was saline solution. 
Prazosin (non-specific antagonist of alpha1-adrenoceptor) were used in a 
concentration of 0.05 mg/ Kg. The solution vehicle was saline solution. 
 
 
2.  Cystometry, tissue harvesting and processing solutions 
 
During cystometry, saline solution was infusecd (1.8 mL/ h) into the bladder 
dome of anaesthetized animals (urethane 1.2 mg/ Kg). 
During perfusion, the fixative and Tyrode´s solution were prepared as follows: 
- Paraformaldehyde 4% (for 1L): 250 mL paraformaldehyde 16%, 250 mL 
Phosphate buffer 0,4M pH 7.2 and 500 mL bidestilled water);  
- Tyrode’s solution (for 1L): 6.80g NaCl; 0.40g KCl; 0.32g MgCl2.6H2O; 0.10g 
MgSO4.7H2O; 0.17g NaH2PO4.H20; 1.00g glucose and 2.20g NaHCO3).  
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 L6-S1 spinal cord segments were sectioned at 40 µm and the cuts were stored 
at -20ᵒC in crioprotectant. To prepare this solution, 500 mL of phosphate buffer 0.1M 
pH 7.2, 300g of sucrose and 300 mL of ethyleneglycol were used 
 
3. Immunoreaction against Fos in spinal cord segments 
 
L6-S1 spinal cord segments were sectioned and immunostained for Fos protein, 
like described below: 
 The segments were washed 3 times with PBS (5 minutes each), following a 
wash with ethanol 50% in elix for 10 minutes, to permeabilize the membranes and 
allow better entry of the substrate.  
The slides were incubated in ethanol 50% and 330 µL of H2O2 for 30 minutes, to 
inhibit the endogenous peroxidase. After this, the sections were washed with ethanol 
50% for 10 minutes and with PBS for 5 minutes.  
Next, the slides were incubated with PBST/ NSS 10% for 1 hour. 
Afterwards, there was an incubation in the primary antibody α- c Fos 
(Calbiochem) diluted 1: 10000 in PBST/ NSS 2% for 2 days at 4ᵒC.  
The slides were washed 3 times (10 minutes each) with PBST/ NSS 2% and 
incubated with secondary antibody biotinylated swine α-rabbit (Palex Medical) diluted 
1:200 in PBST/NSS 2% for 1 hour.  
Then, the slides were washed twice (10 minutes each) with PBST/ NSS 2%, 
with PBST for 10 minutes and incubated with ABC, during at least one hour, to amplify 
the final signal (avidin binds to the biotin of the secondary antibody).  
Next, the slides were washed 3 times with PBST (for 10 minutes each time), 
with PBS for 10 minutes and with Tris-HCl 0,1M for 10 minutes, to remove the excess 
of secondary antibody- ABC complex, or just ABC. 
The slides were incubated with diaminobenzidine (DAB), which is a 
chromogenic substrate of peroxidase. In the presence of H2O2, the enzyme forms a 
brown and insoluble precipitate where there is enzyme, and therefore  the antigen 
under study.  
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Finally, the sections were washed with Tris-HCl 0,1 M for 5 minutes and with 
PBS for 5 minutes. Finally, the slides were mounted with EuKit (National Diagnostics) 
and observed on light microscopy (Zeiss Axioskop 40). 
 
 
4. Immunoreaction against caspase 3 in bladder sections 
 
Bladder sections were immunoreacted against caspase 3, a marker of cellular 
apoptosis, to analyze urothelium integrity.  
Briefly, the slides were washed 3 times with xylene (5 minutes each time), 
washed with ethanol 100% 3 times (5 minutes each), 3 times with ethanol 90% (for 5 
minutes each), 3 times with ethanol 75% (for 5 minutes each) and 3 times with distilled 
water (for 5 minutes each).  
Then, slides were incubated with citrate buffer 2 g/L pH 6, in the microwave for 
15 minutes, and left to cool, for 30 minutes.  
After this, the slides were washed with PBS 2 times (for 10 minutes each), with 
1% H2O2 in methanol for 10 minutes and with PBS for 10 minutes. 
Next, the slides were incubated with PBST/NSS 10% for 1h and, after this, with 
primary antibody rabbit anti-caspase 3 (Abcam) diluted 1:500 in PBST/NSS 2% for 2 
days at 4ᵒC.  
The slides were washed with PBST/NSS 2% 3 times for 10 minutes each time, 
and incubated with secondary antibody 488 goat anti-rabbit 1:3000 (Invitrogen) in 
PBST/NSS 2% for 1h.  
After this, the slides were washed with PBST/NSS 2% 2 times (10 minutes 
each), with PBST for 10 minutes and with PBS for 10 minutes. 
Finally, the slides were mounted with glycerol and observed on fluorescence 
microscope (Zeiss Apotome). 
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5. Preparation of solutions for immunoreaction 
 
Phosphate buffered saline (PBS) is a buffered solution used in biological 
research, and containing sodium chloride, sodium phosphate and, in some cases, 
potassium chloride and potassium phosphate. This solution helps to maintain a 
constant pH. PBST results from addition of Tween 20 or Triton X-100 to PBS. The 
Triton X-100 permeabilizes the cells, facilitating the entry of the antibody into the cells. 
PBS 0.1M (for 1L): 100 mL of stock solution of PBS 10x and 900 mL of distilled 
water. 
 PBST (for 1L): 888 mL of distilled water, 100 mL of PBS 10x and 12 mL of 
Triton X-100 at 25%. 
Triton X-100 25% (for 12 ml): 3 mL of Triton X-100 and 9 mL of distilled water. 
 PBST/ NSS 10% contains PBST and NSS (normal swine serum).  
PBST/NSS 10% (for 8 mL): 800 µL of NSS and 7.2 mL of PBST.  
PBST/NSS 2% (for 8 mL): 160 µL of NSS and 7.84 mL of PBST. 
 For incubation with ABC (Vector Laboratories), use 1 µL of A and 1 µL of B per 
200 µL of PBST. For example, to prepare 3.2 mL of PBST is necessary to add 16 µL of 
A and 16 µL of B. This solution needs to be prepared, at least, 30 minutes prior to use 
and placed in the shaker. 
 To prepare DAB (diaminobenzidine), first add 5 µL of H2O2 at 30% in 20 mL of 
Tris-HCl (0,05 M pH=7.6), and then add 10 mg of DAB.  
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6. Hematoxylin-Eosin staining in bladder sections 
 
Bladder sections were washed with xylene for 10 minutes, to remove paraffin.  
After this, the slides were washed with ethanol 100% (2 minutes), ethanol 90% 
(2 minutes) and ethanol 70% (2 minutes).  
The slides were washed with water for 10 minutes, and then the cuts were 
stained with Hematoxylin for 3 minutes.  
After staining, the slides were placed under current water for 15 minutes.  
Then, the slides were stained with eosin for 30 seconds, and washed with 
ethanol 70%, ethanol 90% and ethanol 100% (only for some seconds in each one). 
The slides were washed with xylene for 10 minutes, mounted with EuKit and 
observed under the light microscope. 
 
 
 
7. Toluidine Blue staining in bladder sections 
 
Bladder sections were washed with xylene for 10 minutes to remove paraffin. 
After this, the slides were washed with ethanol 100% (2 minutes), ethanol 90% 
(2 minutes) and ethanol 70% (2 minutes).  
The slides were washed with water for 10 minutes, and then the cuts were 
stained with Toluidine Blue for 4 minutes.  
After staining, the slides were placed under current water for 15 minutes.  
Then, the slides were washed with ethanol 70%, ethanol 90% and ethanol 
100% (only for some seconds in each one).  
The slides were washed with xylene for 10 minutes, mounted with EuKit and 
observed under the light microscope. 
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